Awards

Introducing the Pharmaceutical Technology Excellence Awards 2024

The 2024 Pharmaceutical Technology Excellence Awards are open for submissions. Download our Research Guide for more details.

The Pharmaceutical Technology Excellence Awards celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognize the people and companies that are driving change.

Our programme is designed to highlight excellence within the sector assessing a variety of corporate activities including deals, business projects and company initiatives – both internal and within the community.

How to take part in the Excellence Awards

To learn how to enter your organisation for the awards, please download the Research Guide. This comprehensive guide provides details on the necessary submission information, and the process for submitting information to us.

Download our Research Guide for more information

How the Excellence Awards work

Companies and institutions undergo evaluation based on their performance in 12 key Areas of Excellence, supported by evidence from both our research and ranking submission process.

  • Business Expansion
  • Diversity
  • Environmental
  • Financing
  • Innovation
  • Investments
  • M&A
  • Marketing
  • Product Launches
  • Research and Development
  • Safety
  • Social

For comprehensive details on our methodology and scoring system, please download the Research Guide.

Making the most of your award win

Participating in the Excellence Awards offers your company numerous benefits, including the ability to showcase your achievements to the market and attract new prospective clients.

For a comprehensive understanding of the benefits, the scale of our audience, and the marketing packages available, please download the Research Guide or contact Tina Ross at tina.ross@globaldata.com.

Frequently-Asked-Questions (FAQ)

Are there any associated costs with the awards?
While there is no fee for submitting information, we offer a variety of packages to enhance your exposure and promote your success to our audience. For details, please contact Tina Ross at tina.ross@globaldata.com.

What sort of projects can I submit as case studies?
Ensure that case studies align with one of our 12 Areas of Excellence. Refer to the examples provided under each category in the following section for guidance.

I’d like to submit a case study, but I’m unsure about the appropriate category for submission
Submission for a specific category is not mandatory; we will consider relevant case studies for all applicable categories.

How will our case study be used?
Case study details may be published with your ranking. If there are specific details you prefer not to be disclosed, please clearly state this in the description.

I would like to submit a long-term project as a case study. Is it eligible for consideration in this year’s research?
The project will be considered valid if a substantial amount of work has been undertaken during the research period.

Can I get an extension to the submission deadline?
​​​​​​​
Kindly email your extension request along with the desired duration to our research team.

Contact Us

For more information on the awards and our methodology, please contact Tina Ross at tina.ross@globaldata.com.

Go to article: Home | Left in limbo: When pharma halts rare disease researchGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: FaravelliGo to article: In DepthGo to article: Left in limbo: When pharma halts rare disease research Go to article: Capturing the genAI boom for drug developmentGo to article: Too much data: a burden or a blessing? Go to article: South Korea seeks to accelerate drug reimbursement administration process Go to article: Sponsors must take on FDA’s diversity guidance to improve community trust Go to article: DelSiTech Company InsightGo to article: Thematic Take: CybersecurityGo to article: Thematic Take: contentsGo to article: Foreword: Cybersecurity in the age of AI Go to article: Navigating the AI-driven cybersecurity landscapeGo to article: Key trends impacting cybersecurity Go to article: Timeline: a history of cybersecurity Go to article: Explainer: The most common types of cyberattacks Go to article: The impact of cybersecurity on healthcareGo to article: Case studies: cybersecurity in healthcare Go to article: Leading cybersecurity adopters and providers in healthcareGo to article: AI attacks now ‘the main cybersecurity concern’ for businesses across sectors Go to article: The state of cybersecurity: AI and geopolitics mean a bigger threat than ever Go to article: Companies’ own AI applications are ‘a huge cybersecurity problem’ Go to article: How healthcare cybercrime is predicted to escalate Go to article: The lasting impacts of the pandemic on cybersecurity in healthcare Go to article: Cyberattacks on healthcare: Russia’s tool for mass disruption Go to article: Traceability technologies tighten supply chain fakery Go to article: Deal activity related to cybersecurity in the pharma industry since 2021 Go to article: Regulators must protect the cybersecurity market from a private equity takeover Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: XylemGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue